NEW NANOTHERAPY RESEARCH FOR INFLAMMATORY BOWEL DISEASES
THE NEW DEAL CONCEPT COULD REVOLUTIONIZE IBD THERAPIES FOR THE GREAT BENEFIT OF PATIENTS AND EUROPEAN HEALTHCARE SYSTEMS.
- Dr. Fabrice NAVARRO, New Deal Project Coordinator
THE PROJECT GOALS
THE PROJECT GOALS
The NEW DEAL project aims to develop a highly selective and local therapy with an improved efficacy and safety profile for IBD patients. This treatment might be an alternative to the existing therapies.
Design and validate a radically improved IBD therapy that specifically targets JAK1 / JAK3 inhibition by means of siRNA and RNAi interference.
Develop advanced technologies for delivering siJAK1 / siJAK3 locally to the inflamed gut
Promote the clinical translation and the future industrial transfer of this new clinical product for IBD therapy.
THE PROJECT NEWS
March New Deal Reads
Lipid-based nanoformulations in the treatment of neurological disorders. Pottoo et al. 2020. Drug Metabolism Reviews. Neurological disorders [...]
February New Deal Reads
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease. Sandborn et al. 2020. [...]
September New Deal Reads
1. siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease. Russo I. et al. 2017. Transl Med [...]
Living with IBD: lost in diagnosis
Among all the diseases similar to IBD, most of the wrong diagnostics come when IBD gets confused with [...]
THE PROJECT PARTNERS
THE PROJECT PARTNERS
